Why the study?
Does platelet function test-guided treatment with P2Y12 inhibitors reduce all-cause mortality at 1 year in patients with acute myocardial infarction compared to unguided treatment?
Does platelet function test-guided treatment with P2Y12 inhibitors reduce all-cause mortality at 1 year in patients with acute myocardial infarction compared to unguided treatment?
In patients with acute myocardial infarction, platelet function test-guided P2Y12 inhibitor therapy with targeted switching to prasugrel significantly reduced 1-year all-cause mortality compared to unguided therapy.
Answers are grounded in this paper and cite their sources.
PFT-guided P2Y12 therapy was associated with lower 1-year mortality in AMI; leaves open whether randomized trials will confirm benefit.
inhibitor in both groups (unguided: 96% vs PFT guided: 85%, p <0.001). In the PFT-guided group, 19% of patients had HPRoC and 77% of them were switched to prasugrel. According to the adjusted analysis, all-cause mortality at 1 year was significantly lower in the PFT-guided compared with the unguided group (hazard ratio 0.57 [95% confidence interval 0.43 to 0.77], p <0.001). Although prasugrel treatment was not associated with lower all-cause mortality in the overall cohort, patients with HPRoC who switched to prasugrel had significantly lower mortality when compared with those continuing clopidogrel (hazard ratio 0.33 [95% confidence interval 0.12 to 0.92], p <0.05). In conclusion, in patients with AMI, PFT-guided treatment with a high rate of switchover to prasugrel was associated with a lower risk of mortality. Prasugrel was a predictor of lower mortality in patients with HPRoC but not in the overall cohort of AMI.
No takes yet. Share an insight, caveat, or question.
Komócsi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: